Results 271 to 280 of about 936,523 (298)

Chimeric antigen receptor T‐cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice

Ca-A Cancer Journal for Clinicians, 2023
Rujul H Parikh, Sagar Lonial
exaly  

CA 19-9 and Lewis Antigens in Pancreatic Cancer

Journal of Clinical Oncology, 2009
openaire   +2 more sources

Tumour Markers in Uraemia: Carbohydrate Antigen CA 72–4, Carcinoembryonic Antigen and Carbohydrate Antigen CA 19–9

Annals of Clinical Biochemistry: International Journal of Laboratory Medicine, 1996
L, Fernández-Fernández, M, Asensio, E, Tejero, L, Rabadán, L, Lopez   +4 more
openaire   +2 more sources

[Importance of the tumor-associated antigen CA 19-9 in the differential diagnosis of pancreatic diseases].

Deutsche medizinische Wochenschrift (1946), 1985
Tumour-associated antigen CA 19-9 was determined in serum from 166 patients (30 without gastro-intestinal disease, 32 with liver cirrhosis, 9 with choledocholithiasis, 65 with acute or chronic pancreatitis and 30 with malignant tumors in the region of pancreas and bile passages).
G, Heptner, S, Domschke, M U, Schneider, W, Domschke   +3 more
openaire   +1 more source

[Serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA 19-9) values in patients with pancreatic cancer or pancreatitis].

Changgeng yi xue za zhi, 1991
For evaluating the diagnostic rate of serum CA19-9 and carcinoembryonic antigen (CEA) in pancreatic malignancies and pancreatitis, 22 patients with pancreatic malignancy, 27 patients with acute pancreatitis and 7 patients with chronic pancreatitis were included in this prospective study.
C S, Changchine, C Y, Yung, K Y, Tzen
openaire   +1 more source

Elevation of a tumor associated antigen CA 19-9 levels in patients with rheumatic diseases.

The Journal of rheumatology, 1990
We investigated the incidence and characteristics of an elevated tumor associated antigen CA 19-9 in patients with rheumatic diseases. Serum concentration of CA 19-9 was increased in 13 of 39 patients (33.3%) with definite or classical rheumatoid arthritis (RA), in 6 of 19 patients (31.6%) with systemic lupus erythematosus (SLE), in 3 of 9 patients (33.
C, Shimomura, K, Eguchi, A, Kawakami, K, Migita, H, Nakao, T, Otsubo, Y, Ueki, H, Tezuka, S, Yamashita, M, Matsunaga   +9 more
openaire   +1 more source

A guide to antigen processing and presentation

Nature Reviews Immunology, 2022
Novalia Pishesha, Thibault J Harmand, Hidde L Ploegh   +2 more
exaly  

Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity

Cell, 2023
Leyuan Ma
exaly  

MR1 antigen presentation to MAIT cells and other MR1-restricted T cells

Nature Reviews Immunology, 2023
Hamish E G Mcwilliam, JOSÉ A Villadangos, Villadangos JOSÉ A   +2 more
exaly  

GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity

Cancer Cell, 2022
Sabine Heitzeneder, Robbie G Majzner, Shaurya Dhingra   +2 more
exaly